Cacoub et al review the common entity cryoglobulinemic vasculitis (CryoVas) in the current issue of the American Journal of Medicine.
This small-vessel vasculitis involves the skin, joints, and potentially other organs, including the peripheral nervous system or the kidneys.
Methotrexate is a mainstay drug in the treatment of rheumatoid arthritis (RA). Yet, we may not be using it long enough or optimizing its use.
The American College of Physicians released a position paper exploring factors driving the growth of “concierge” and other “direct patient contracting practices” (DPCPs) and the “limited” evidence on their impact on patient care.
What do you tell your patients who are considering augmentation mammoplasty? Or who question the safety of prior implants?
Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).
Clements et al presented the results of their Scleroderma Lung Study II wherein PSS patients with interstitial lung disease were randomized to receive either 3 grams daily of mycopheonolate or 2mg/kg/day of cyclophosphamide.
Liu and coworkers from Boston presented abstract #1213, with data from the NHS II Survey. They examined 93,859 women (without RA) and their dietary data from 1991 to 2011.
Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.
TNF blocker Induced Psoriasis: Take Home Messages
A study of 194 knee OA patients received either 1200 mg chondroitin sulfate or celecoxib 200 mg daily, and clinical and MRI outcomes were assessed at 1 and 2 years.
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
In September, the FDA issued warnings that the dipeptidyl peptidase-4 (DPP4) inihibitor Invokana may cause a dose-dependant increased risk of bone fractures. This was based on a review of nin
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
